Search This Blog

Friday, June 2, 2023

LAVA: Janssen Picks Lead Antibody to Move Toward Clinical Development

 

  • Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.

  • In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery and development of novel bispecific antibody-based gamma delta T cell engagers for the treatment of cancer. The agreement was facilitated by Johnson & Johnson Innovation.

  • LAVA is also eligible to receive potential development, regulatory and commercialization milestone payments and tiered royalties.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.